TY - JOUR
T1 - Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation
T2 - An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial
AU - Eikelboom, John W.
AU - Wallentin, Lars
AU - Connolly, Stuart J.
AU - Ezekowitz, Mike
AU - Healey, Jeff S.
AU - Oldgren, Jonas
AU - Yang, Sean
AU - Alings, Marco
AU - Kaatz, Scott
AU - Hohnloser, Stefan H.
AU - Diener, Hans Christoph
AU - Franzosi, Maria Grazia
AU - Huber, Kurt
AU - Reilly, Paul
AU - Varrone, Jeanne
AU - Yusuf, Salim
PY - 2011/5/31
Y1 - 2011/5/31
N2 - Background-: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and results-: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged
AB - Background-: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and results-: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged
KW - anticoagulants
KW - atrial fibrillation
UR - http://www.scopus.com/inward/record.url?scp=79958126202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958126202&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.110.004747
DO - 10.1161/CIRCULATIONAHA.110.004747
M3 - Article
C2 - 21576658
AN - SCOPUS:79958126202
VL - 123
SP - 2363
EP - 2372
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 21
ER -